Assertio Holdings, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating Activities
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization
Amortization of debt discount, debt issuance costs and royalty rights
Amortization of debt issuance costs and Royalty Rights
Amortization of debt issuance costs
Accretion of interest income from short-term investments
Loss on impairment of intangible assets
Gain on extinguishment of debt
Senior Notes
Total gain on extinguishment of debt

Recurring fair value measurement of assets and liabilities
Impairment of intangible assets
Loss on Assertio Therapeutics divestiture
Recurring fair value measurements of assets and liabilities
Payment of contingent consideration
Debt-related expenses
Stock-based compensation
Provisions for inventory and other assets
Loss on impairment of goodwill
Loss on disposal of equipment and early termination of leases
Income tax provision
Gain (loss) on sale
Deferred income taxes
Provisions for inventory
Changes in assets and liabilities, net of acquisition:
Accounts receivable
Inventories
Prepaid and other assets
Income taxes
Accounts payable and other accrued liabilities
Accrued rebates, returns and discounts
Interest payable

Net cash (used in) provided by operating activities
Investing Activities
Assertio Therapeutics divestiture
Proceeds from maturities of short-term investments
Proceeds from the sale of investments
Net cash acquired in Spectrum Merger
Proceeds from sale
Purchases of property and equipment
Purchase of Sympazan
Purchases of short-term investments
Net cash used in investing activities

Financing Activities
Proceeds from issuance of 2027 Convertible Notes
Payments related to the vesting and settlement of equity awards, net
Payment of contingent consideration
Payments in connection with Senior Notes settlement
Proceeds from issuance of common stock
Proceeds from exercise of stock options
Payments in connection with 2027 Convertible Notes
Payment in connection with 2024 Senior Notes
Payment of debt issuance costs
Payment of direct transaction costs related to convertible debt inducement
Payments on Revolver
Payment of Royalty Rights
Other financing activities
Net cash used in financing activities

Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental Disclosure of Cash Flow Information
Net cash paid for income taxes
Cash paid for interest
Deferred payments for acquisition of Otrexup intangible assets

Comments